NKTR PE Ratio & Valuation,Is NKTR Overvalued

NKTR Relative Valuation

NKTR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NKTR is overvalued; if below, it's undervalued.

Historical Valuation

Nektar Therapeutics (NKTR) is now in the Overvalued zone, suggesting that its current forward PS ratio of 27.59 is considered Overvalued compared with the five-year average of -2.89. The fair price of Nektar Therapeutics (NKTR) is between 14.40 to 49.37 according to relative valuation methord. Compared to the current price of 54.70 USD , Nektar Therapeutics is Overvalued By 10.8%.

Relative Value

Fair Zone

14.40-49.37

Current Price：54.70

10.8%

Overvalued

-5.81

-5.47

EV/EBITDA

Nektar Therapeutics. (NKTR) has a current EV/EBITDA of -5.47. The 5-year average EV/EBITDA is -2.15. The thresholds are as follows: Strongly Undervalued below -6.69, Undervalued between -6.69 and -4.42, Fairly Valued between 0.12 and -4.42, Overvalued between 0.12 and 2.39, and Strongly Overvalued above 2.39. The current Forward EV/EBITDA of -5.47 falls within the Undervalued range.

-6.43

EV/EBIT

Nektar Therapeutics. (NKTR) has a current EV/EBIT of -6.43. The 5-year average EV/EBIT is -2.08. The thresholds are as follows: Strongly Undervalued below -6.57, Undervalued between -6.57 and -4.33, Fairly Valued between 0.17 and -4.33, Overvalued between 0.17 and 2.41, and Strongly Overvalued above 2.41. The current Forward EV/EBIT of -6.43 falls within the Undervalued range.

27.59

Nektar Therapeutics. (NKTR) has a current PS of 27.59. The 5-year average PS is 10.78. The thresholds are as follows: Strongly Undervalued below -11.12, Undervalued between -11.12 and -0.17, Fairly Valued between 21.73 and -0.17, Overvalued between 21.73 and 32.68, and Strongly Overvalued above 32.68. The current Forward PS of 27.59 falls within the Overvalued range.

-4.94

P/OCF

Nektar Therapeutics. (NKTR) has a current P/OCF of -4.94. The 5-year average P/OCF is -3.51. The thresholds are as follows: Strongly Undervalued below -9.86, Undervalued between -9.86 and -6.68, Fairly Valued between -0.33 and -6.68, Overvalued between -0.33 and 2.85, and Strongly Overvalued above 2.85. The current Forward P/OCF of -4.94 falls within the Historic Trend Line -Fairly Valued range.

-6.25

P/FCF

Nektar Therapeutics. (NKTR) has a current P/FCF of -6.25. The 5-year average P/FCF is -1.68. The thresholds are as follows: Strongly Undervalued below -19.32, Undervalued between -19.32 and -10.50, Fairly Valued between 7.15 and -10.50, Overvalued between 7.15 and 15.97, and Strongly Overvalued above 15.97. The current Forward P/FCF of -6.25 falls within the Historic Trend Line -Fairly Valued range.

Nektar Therapeutics (NKTR) has a current Price-to-Book (P/B) ratio of 12.65. Compared to its 3-year average P/B ratio of 1.83 , the current P/B ratio is approximately 592.65% higher. Relative to its 5-year average P/B ratio of 2.14, the current P/B ratio is about 490.76% higher. Nektar Therapeutics (NKTR) has a Forward Free Cash Flow (FCF) yield of approximately -17.11%. Compared to its 3-year average FCF yield of -118.52%, the current FCF yield is approximately -85.57% lower. Relative to its 5-year average FCF yield of -82.84% , the current FCF yield is about -79.35% lower.

12.65

P/B

Median3y

1.83

Median5y

2.14

-17.11

FCF Yield

Median3y

-118.52

Median5y

-82.84

Competitors Valuation Multiple

The average P/S ratio for NKTR's competitors is 371.71, providing a benchmark for relative valuation. Nektar Therapeutics Corp (NKTR) exhibits a P/S ratio of 27.59, which is -92.58% above the industry average. Given its robust revenue growth of -51.13%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of NKTR increased by 292.11% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -2.00 to -6.93.

The secondary factor is the Margin Expansion, contributed 96.14%to the performance.

Overall, the performance of NKTR in the past 1 year is driven by P/E Change. Which is more unsustainable.

-51.13%

24.12M → 11.79M

Revenue Growth

96.14%

-153.61 → -301.29

Margin Expansion

247.10%

-2.00 → -6.93

P/E Change

292.11%

13.95 → 54.70

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Nektar Therapeutics (NKTR) currently overvalued or undervalued?

What is Nektar Therapeutics (NKTR) fair value?

NKTR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Nektar Therapeutics (NKTR) is between 14.40 to 49.37 according to relative valuation methord.

How does NKTR's valuation metrics compare to the industry average?

What is the current P/B ratio for Nektar Therapeutics (NKTR) as of Dec 15 2025?

As of Dec 15 2025, Nektar Therapeutics (NKTR) has a P/B ratio of 12.65. This indicates that the market values NKTR at 12.65 times its book value.

What is the current FCF Yield for Nektar Therapeutics (NKTR) as of Dec 15 2025?

As of Dec 15 2025, Nektar Therapeutics (NKTR) has a FCF Yield of -17.11%. This means that for every dollar of Nektar Therapeutics’s market capitalization, the company generates -17.11 cents in free cash flow.

What is the current Forward P/E ratio for Nektar Therapeutics (NKTR) as of Dec 15 2025?

As of Dec 15 2025, Nektar Therapeutics (NKTR) has a Forward P/E ratio of -5.81. This means the market is willing to pay $-5.81 for every dollar of Nektar Therapeutics’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Nektar Therapeutics (NKTR) as of Dec 15 2025?

As of Dec 15 2025, Nektar Therapeutics (NKTR) has a Forward P/S ratio of 27.59. This means the market is valuing NKTR at $27.59 for every dollar of expected revenue over the next 12 months.

NKTR Valuation